Table 4.
Serious cardiovascular event comparison of nine VEGFR-TKIs
| AXI | |||||||||
|
1.76 (0.36, 9.27) |
CAB | ||||||||
|
0.42 (0.09, 2.09) |
0.24 (0.05, 1.02) |
LEN | |||||||
|
2.97 (0.67, 14.63) |
1.71 (0.40, 7.05) |
7.10 (1.60, 31.96) ƚ |
NIN | ||||||
|
3.10 (0.71, 14.98) |
1.77 (0.47, 7.17) |
7.37 (1.81, 34.94) ƚ |
1.05 (0.28, 4.17) |
PAZ | |||||
|
20.00 (6.00, 77.34) ƚ |
11.40 (4.14, 33.87) ƚ |
47.29 (15.29, 163.22) ƚ |
6.71 (2.41, 20.69) ƚ |
6.47 (2.83, 15.08) ƚ |
PLA | ||||
|
3.90 (0.93, 17.80) |
2.21 (0.61, 8.03) |
9.16 (2.41, 38.42) ƚ |
1.30 (0.35, 4.89) |
1.24 (0.41, 3.74) |
0.19 (0.09, 0.39)* |
REG | |||
|
2.68 (0.95, 8.72) |
1.54 (0.50, 4.93) |
6.38 (2.26, 20.43) ƚ |
0.91 (0.31, 2.75) |
0.87 (0.31, 2.44) |
0.14 (0.07, 0.25)* |
0.70 (0.27, 1.81) |
SOR | ||
|
2.78 (0.73, 11.51) |
1.60 (0.52, 4.72) |
6.64 (2.21, 21.44) ƚ |
0.93 (0.30, 3.01) |
0.90 (0.28, 2.78) |
0.14 (0.06, 0.28)* |
0.73 (0.25, 2.04) |
1.03 (0.46, 2.27) |
SUN | |
|
1.50 (0.26, 8.14) |
0.85 (0.17, 3.81) |
3.59 (0.65, 18.07) |
0.50 (0.10, 2.38) |
0.47 (0.11, 1.83) |
0.07 (0.02, 0.21)* |
0.39 (0.09, 1.37) |
0.55 (0.14, 1.87) |
0.53 (0.12, 1.95) |
VAN |
Data presented with ORs (95% CrI) in the column-defining drug compared with the row-defining drug
OR odds ratio, CrI credible interval, PLA placebo, AXI axitinib, CAB cabozantinib, LEN lenvatinib, NIN nintedanib, PAZ pazopanib, REG regorafenib, SOR sorafenib, SUN sunitinib, VAN vandetanib
*ORs more than 1 favors row-defining drug
ƚ ORs less than 1 favors column-defining drug